| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.35 | 5e-13 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.34 | 2e-10 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.22 | 5e-10 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.26 | 5e-07 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.15 | 2e-06 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | 0.22 | 6e-05 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.17 | 6e-05 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | 0.21 | 7e-05 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.13 | 8e-05 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0001 |